2015, № 12 (187)

Panova I.E., Zhiliaeva О.V., Shaimov T.B., Abdulaeva E.A. COURSE OF CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH NEOVASCULAR STAGE AGE-MACULAR DEGENERATION AND AXIAL MYOPIA ON THE BACKGROUND OF ANTI-VEGF THERAPYThe current age-related macular degeneration (AMD) and axial myopia (OM) may be accompanied by development of choroidal neovascularization (CNV), which leads to in permanent decrease of visual functions in patients. The combination of AMD and OM in clinical practice not uncommon which complicates the disease. Anti-VEGF therapy is a drug therapy CNV resolution in the Russian Federation. Comparative analysis of the parameters of optical coherence tomography (OCT) and data visometry in 37 patients (40 eyes) with neovascular stage age-related macular degeneration (AMD), and 23 patients (26 eyes) with AMD, occurring against the backdrop of axial myopia who received treatment intravitreal injections ranibizumab to clinical stabilization process in the study conducted. Mostly occult choroidal neovascularization occurred in both treatment groups. Positive results were obtained in both groups: the maximum increase in visual acuity occurred after the fourth injection, improvements in OCT — after the first injection. The best therapeutic response in a fit of the retinal pigment epithelium detachment in patients diagnosed with AMD, while the best performance in the treatment of comorbidity achieved a reduction of neuroepithelial detachment and cystoid changes of retinal.Key words: age-related macular degeneration, myopia, ranibizumab, choroidal neovascularization.

Download

References:

1. Boyko EV Age-related macular degeneration (risk factors, classification, diagnosis, prevention, treatment) / EV Boyko, LV Zhuravlev, SV Sosnowski // Guidelines. — M. — 2010. — P. 71.

2. Budzinskaya MV Contemporary pharmacogenetic approaches to the treatment of age-related macular degeneration / MV Budzinskaya, TV Weather, EV Generozov [et al.] // Bulletin of ophthalmology. — 2013. — №5. — P. 127-135.

3. Zaitseva NV Clinical criteria for the differential diagnosis of myopic choroidal neovascularization, wet form of age-related macular degeneration / NV Zaitsev, IV Zlobin, TN St. George [et al.] // VI All-Russian seminar-roundtable "Macula". — Rostov-but-Don. — 2014. — P. 504-505.

4. Panova IE The spectral optical coherence tomography in the evaluation of early and intermediate stages of age-related macular degeneration / IE Panova, ER Nikitin M.Yu. Prokopeva // BC. Clinical Ophthalmology. — 2010. — V. 11. — № 1. — P. 8-11.

5. Panova IE Clinical and monitoring tool in assessing the effectiveness of different treatment options for neovascular age-related macular degeneration / IE Panova, MY Prokopiev, ON Avdeeva [et al.] // Bulletin of the Orenburg State University. — 2011. — № 14 (133). — P. 292-294.

6. Urneva EM Wet age-related macular degeneration: classification criteria based on indicators of optical coherence tomography High-resolution / EM Urneva, SA Alpatov // Bulletin of the East Siberian Scientific Center of the Academy of Medical Sciences. — 2009. — № 5-6. — P. 41-45.

7. Finger R.P. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration / RP Finger, SS Wickremasinghe, PN Baird [et al.] // Surv. Ophthalmol. — 2014 Jan-Feb; 59(1):1-18.

8. Kovach J.L. Anti-VEGF Treatment Strategies for Wet AMD / J.L. Kovach, G. S. Stephen, W.F. Harry [et al.] // Journal of Ophthalmology. — Vol. 2012 (2012). — Art. ID 786870. — P. 7.

9. Mitchell P. et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials // British Journal of Ophthalmology. — Vol. 94. — №1. — 2010. — P. 2–13.

10. Nguyen Q.D., Heier J., Brown D. et al. Randomized, double-masked, active-controlled phase 3 trial of the efficacy and safety of intravitreal VEGF-Trap-Eye in wet AMD: one-year results of the VIEW-1 study // In Proceedings of the Association for Research in Vision and Ophthalmology. — 2011. — №3073. — Fort Lauderdale. — Fla. — USA.

11. Rosenfeld P.J. Ranibizumab for neovascular age-related macular degeneration / PJ Rosenfeld, DM Brown, JS Heier et al. // N. Engl. J. Med. — 2006. — Vol. 355. — P. 1419 — 1431.

12. Ruiz-Moreno J.M. et al. Intravitreal anti-VEGF therapy for choroidal neovascularization secondary to pathological myopia: 4-year outcome // Br J Ophthalmol. — 2013. — №97. — P. 1447-1450.

13. Schmidt-Erfurth U. at al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration. The EXCITE study // Ophthalmology. — Vol. 118. — 2010. — P. 831–839.

14. Tufail А. et al. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study // Eye. — 2013. — № 27. — P. 709–715, doi: 10. 1038 / eye. 2013.8. — Epab. 213, Mar.1.

15. Vision loss in younger patients: a review of choroidal neovascularization / DG Miller, LJ Singerman // Optom Vis. Sc. — 2006. — May; 83(5):316-25.

About this article

Authors: Zhilyaeva O.V., Panova I.E., Shaimov T.B., Abdulaeva E.A.

Year: 2015

Editor-in-chief

Sergey Aleksandrovich
MIROSHNIKOV

© Электронное периодическое издание: ВЕСТНИК ОГУ on-line (VESTNIK OSU on-line), ISSN on-line 1814-6465
Зарегистрировано в Федеральной службе по надзору в сфере связи, информационных технологий и массовых коммуникаций
Свидетельство о регистрации СМИ: Эл № ФС77-37678 от 29 сентября 2009 г.
Учредитель: Оренбургский государственный университет (ОГУ)
Главный редактор: С.А. Мирошников
Адрес редакции: 460018, г. Оренбург, проспект Победы, д. 13, к. 2335
Тел./факс: (3532)37-27-78 E-mail: vestnik@mail.osu.ru